Galapagos NV

( )
GLPG After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -1.41%171.810.0%$763.68m
AMGNAmgen, Inc. -1.48%248.351.5%$601.54m
VRTXVertex Pharmaceuticals, Inc. -1.22%292.161.9%$427.81m
GILDGilead Sciences, Inc. -1.09%62.451.0%$396.17m
REGNRegeneron Pharmaceuticals, Inc. -2.74%623.902.6%$359.24m
NVAXNovavax, Inc. -2.47%40.3475.7%$337.27m
SNSSSunesis Pharmaceuticals, Inc. 9.21%4.030.7%$281.71m
ILMNIllumina, Inc. 0.06%227.443.3%$245.24m
BIIBBiogen, Inc. -1.28%218.221.8%$201.29m
BNTXBioNTech SE -1.45%158.590.0%$159.39m
GOVXGeoVax Labs, Inc. -1.10%2.700.0%$138.58m
CRSPCRISPR Therapeutics AG -1.79%77.460.6%$118.69m
BMRNBioMarin Pharmaceutical, Inc. -0.97%95.074.2%$100.00m
RYTMRhythm Pharmaceuticals, Inc. -7.26%19.940.0%$93.96m
MRTXMirati Therapeutics, Inc. -3.13%80.451.6%$91.58m

Company Profile

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.